BRAF and melanoma: Recent advances in the treatment of malignant melanoma, such as B-Raf proto-oncogene serine/threonine kinase (BRAF) and mitogen-activated extracellular signal-related kinase (MEK) inhibitors and immune checkpoint inhibitors, have improved the overall survival of the patients [1, 2].